Digital Pathology Image Analysis Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Digital Pathology Image Analysis Market Report Segments the Industry Into by Software (Imaging Management System Software, Image Analysis Software, and More), by Application (Disease Diagnosis, Drug Discovery, and More), by End User (Hospitals and Reference Laboratories, Pharmaceutical and Biotechnology Companies, and More) and Geography. The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Digital Pathology Image Analysis Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Digital Pathology Image Analysis Market with other markets in Healthcare Industry

Digital Pathology Image Analysis Market Analysis by Mordor Intelligence

The global digital pathology image analysis market is valued at USD 419.69 million in 2025 and is forecast to reach USD 650.20 million by 2030, advancing at a 9.15% CAGR over the period. Steady growth stems from expanding adoption of artificial-intelligence tools that cut diagnostic turnaround times, improve slide-level quality control and offset a widening pathologist shortage. North America keeps its lead through early FDA clearances, favourable reimbursement policies and long-standing telepathology networks, whereas Asia-Pacific accelerates fastest on the back of national AI programmes and hospital network modernisation. Software innovation is shifting from rule-based algorithms to large-vision foundation models, opening opportunities in multi-modal tissue analytics and spatial-omics integration. Competitive dynamics remain fragmented, yet recent acquisitions—such as Quest Diagnostics taking over PathAI’s clinical assets—signal a move toward platform consolidation. Implementation costs and data-privacy regulations temper immediate expansion, but updated reimbursement guidance and federated-learning frameworks continue to unlock fresh addressable demand.

Key Report Takeaways

  • By software, image analysis algorithms held 42.67% of the digital pathology image analysis market share in 2024, while AI-powered decision-support suites are set to log a 10.13% CAGR to 2030. 
  • By application, disease diagnosis captured 52.17% of the digital pathology image analysis market size in 2024; drug discovery is projected to expand at a 9.83% CAGR between 2025-2030. 
  • By end user, hospitals and reference laboratories commanded 48.43% of the digital pathology image analysis market size in 2024, whereas pharmaceutical and biotechnology firms are forecast to grow 9.54% through 2030. 
  • By geography, North America led with 48.52% of the digital pathology image analysis market share in 2024; Asia-Pacific is set to post a 10.32% CAGR up to 2030. 

Segment Analysis

By Software: AI-Powered Solutions Drive Market Evolution

The image-analysis-algorithm segment represented 42.67% of 2024 revenue, forming the functional core of most deployments in the digital pathology image analysis market. Continuous enhancements in tile-wise tissue detection, nuclear segmentation and H-score quantification keep this segment indispensable, but revenue growth is slower than AI-driven decision suites. The latter log a 10.13% CAGR, fuelled by FDA breakthroughs for prostate-cancer grading and lung-cancer biomarker quantification. As a result, AI-powered suites are expected to account for 31% of the digital pathology image analysis market size by 2030. Middleware and integration tools secure adoption by bridging laboratory information systems and cloud archives, while open-source environments such as QuPath extensions lower barriers for academic research. Large vision models from HistAI trained on 1.1 million slides shorten development cycles for niche algorithms, driving differentiation.

A parallel shift emerges toward multi-modal orchestration, where image analysis plugs into genomic-variant callers and radiomics dashboards. Vendors offering seamless API layers find favour among enterprise buyers seeking scalable “plug-and-play” ecosystems. Scanners bundled with embedded AI workflows deliver recognisable value propositions to resource-limited hospitals that prefer turnkey packages. Over the forecast window, pricing models are expected to pivot from perpetual licences to annualised software-as-a-service subscriptions, aligning revenue streams with usage volumes and lowering capital hurdles for mid-tier institutions.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Drug Discovery Accelerates Beyond Traditional Diagnosis

Disease diagnosis retained a 52.17% share of the digital pathology image analysis market size in 2024, underpinned by national cancer-screening programmes and hospital modernisation. Automated mitosis counts, PD-L1 scoring and Gleason-grading modules are increasingly standard in tertiary centres. Drug discovery, however, is projected to grow fastest at 9.83% CAGR through 2030 as pharma companies rely on high-throughput digitisation for toxicology studies, image-based biomarkers and adaptive-trial enrichment. Partnerships such as Novartis–Deciphex underline sponsor appetite for validated AI lesion detection in regulated GLP environments. Companion-diagnostic algorithms integrating histology and AI-quantified immunomarkers underpin precision-therapy launches, encouraging broader investment. Educational and teleconsultation subsectors add resilient demand, especially in emerging markets adopting cloud-based curricula to mitigate pathologist shortages.

Remote-second-opinion services record turnaround-time reductions of 30% compared with glass-slide shipping, expanding reach to under-served provinces. Quality-control modules score over 99% sensitivity in flagging artefacts and out-of-focus regions, helping laboratories comply with tightening accreditation norms. Collectively these trends broaden the application spectrum and cement the role of the digital pathology image analysis market in multidisciplinary precision-medicine workflows.

By End User: Pharmaceutical Sector Drives Innovation Adoption

Hospitals and reference laboratories generated 48.43% of 2024 spending, reflecting routine histopathology needs and mandated quality-improvement initiatives. Their demand profile centres on whole-slide scanners, integrated LIS connectors and on-premise archives. Pharmaceutical-biotechnology companies, in contrast, are set to post the highest growth at 9.54% CAGR, propelling algorithm validation and cloud-native infra purchases. Their use cases range from toxicologic-pathology readouts to global study-site harmonisation. Academic institutes leverage open-source tools for spatial-omics research, while contract research organisations capture outsourced study volumes by integrating AI scoring into regulatory submissions. Smaller local labs remain cautious adopters, constrained by capex realities, but new pay-per-scan business models are emerging from platform vendors eager to penetrate this untapped pool of potential users.

Emerging partnership paradigms—such as Charles River teaming with Deciphex—underscore CRO appetite for turnkey AI panels that reduce observer variability and improve lesion-detection time. In parallel, integrated health networks negotiate multi-year enterprise licences that bundle hardware refreshes, maintenance and AI upgrades into predictable operating-expense structures, lowering per-slide costs over contract lifetimes.

Market Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America maintained 48.52% of 2024 revenue, anchored by FDA clearances, early reimbursement frameworks and extensive hospital networks deploying whole-slide imaging at scale. Programmes like Mayo Clinic’s enterprise digital pathology initiative show institutional resolve to embed AI across all subspecialties. Quest Diagnostics’ acquisition of PathAI’s clinical assets deepens platform synergies and speeds AI diffusion in community oncology settings. Barriers persist in independent labs, where a 2024 industry poll revealed just 33% had gone fully digital owing to cost concerns. Nonetheless, cloud-storage price declines and CPT code updates are expected to ease adoption friction.

Asia-Pacific is projected to record a 10.32% CAGR to 2030, the highest among all regions. China’s DeepSeek AI has scaled to over ninety tertiary hospitals, illustrating sovereign AI programmes’ power in transforming care pathways. India’s National Digital Health Mission earmarks funds for telepathology nodes that integrate image archives with electronic-health-record backbones, paving pathways for rural biopsy review. Japanese start-ups such as Medmain raised USD 13.3 million in Series B financing to expand AI-based pathology services, buoyed by growing venture-capital confidence. Infrastructure gaps and disparate regional regulations remain obstacles, yet consortium-led pilots demonstrate that public-private models can overcome resource limitations.

Europe sustains a sizeable footprint despite regulatory headwinds from IVDR and the AI Act. 3DHISTECH secured CE-IVD registration for its PANNORAMIC 1000 scanner, signalling that compliance pathways, though stringent, are navigable. Funding rounds—Visiopharm’s USD 26.3 million raise, for instance—bolster continuous product improvements targeting workflow standardisation. The European Society of Pathology published consensus guidelines emphasising QC metrics, sustainability goals and data-sharing frameworks, aiding harmonised implementation across member states. Telepathology solutions address the continent’s rural-pathologist deficit, although smaller facilities face capital constraints similar to peers elsewhere.

Competitive Landscape

The digital pathology image analysis market shows moderate fragmentation with visible consolidation momentum as diagnostic majors integrate AI upstarts to secure end-to-end portfolios. Quest Diagnostics closed on PathAI’s Memphis lab and licensed the AISight platform, positioning the nation’s largest reference lab to embed algorithmic grading across 7,000 hospitals. LeicaBiosystems’ strategic investment in IndicaLabs pairs the Aperio GT450 scanner family with HALOAP software, offering DICOM-native streaming, remote sign-out, and an AI-apps marketplace under one brand.

Competition now pivots on three axes. First, breadth of AI pipelines: Paige’s Virchow and PRISM foundation suites span17 tissue types, giving early-mover hospitals an avenue to one-contract coverage for multiple cancers. Second, interoperability: open-API designs earn preference as multi-modal datasets flow into cloud laboratory information systems; Aiforia’s2025 pact with Paige demonstrates the vendor-neutral ethos demanded by enterprise buyers. Third, regulatory velocity: Ibex secured CE-IVDR and FDA clearances in rapid succession, winning first-mover contracts at five U.S. integrated-delivery networks.

Emerging disruptors inject fresh capabilities. PictorLabs raised USD48.8million to commercialize AI-based virtual staining that could bypass traditional dyes and save 20minutes per slide. Clarapath amassed USD75million to automate tissue grossing with SectionStar robots, shaving hours off upstream processing and feeding cleaner images downstream. Foundation-model suppliers like HistAI open license programs that let regional vendors fine-tune pretrained weights, eroding entry barriers and spurring localized algorithm ecosystems. Regional specialists persist, providing language-localized interfaces and on-site support; Pathcore in Canada and Deciphex in Ireland illustrate how service proximity preserves competitive tension despite global consolidators.

Digital Pathology Image Analysis Industry Leaders

  1. Danaher Corporation

  2. Koninklijke Philips NV

  3. PathAI, Inc.

  4. Visiopharm A/S

  5. Paige AI, Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Digital Pathology Image Analysis Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2025: Leica Biosystems announced a strategic investment in Indica Labs to combine Aperio scanners with HALO AP software, targeting AI-enabled companion diagnostics and biomarker discovery applications.
  • September 2024: Proscia partnered with Fimlab Laboratories to deploy its Concentriq platform, enabling AI-backed pathology reporting across Finland’s largest regional lab.
  • June 2024: Quest Diagnostics agreed to acquire selected PathAI Diagnostics assets to accelerate AI-supported cancer-diagnosis workflows.

Table of Contents for Digital Pathology Image Analysis Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising adoption of digital pathology to enhance lab efficiency
    • 4.2.2 Increasing application in drug discovery & companion diagnostics
    • 4.2.3 Expanding prevalence of cancer & chronic diseases
    • 4.2.4 Growing integration of AI for automated image analysis
    • 4.2.5 Emergence of spatial-omics integration driving multimodal tissue insights
    • 4.2.6 Uptake of federated learning for privacy-preserving cross-institution training
  • 4.3 Market Restraints
    • 4.3.1 Stringent regulatory concerns for primary diagnosis
    • 4.3.2 High upfront costs & ROI uncertainty for smaller labs
    • 4.3.3 Data-privacy limits on cross-border digital-slide exchange
    • 4.3.4 Scarcity of curated rare-disease datasets for algorithm validation
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Software
    • 5.1.1 Imaging Management System Software
    • 5.1.2 Image Analysis Algorithms
    • 5.1.3 AI-powered Decision-Support Suites
    • 5.1.4 Integration / Middleware Tools
    • 5.1.5 Open-Source & Community Platforms
    • 5.1.6 Others
  • 5.2 By Application
    • 5.2.1 Disease Diagnosis
    • 5.2.2 Drug Discovery
    • 5.2.3 Companion Diagnostics
    • 5.2.4 Education & Training
    • 5.2.5 Teleconsultation & Remote Second Opinion
    • 5.2.6 Quality Control & Regulatory Compliance
  • 5.3 By End User
    • 5.3.1 Hospitals & Reference Laboratories
    • 5.3.2 Pharmaceutical & Biotechnology Companies
    • 5.3.3 Academic & Research Institutes
    • 5.3.4 Contract Research Organizations (CROs)
    • 5.3.5 Others
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Danaher Corp. (Leica Biosystems)
    • 6.3.2 Koninklijke Philips NV
    • 6.3.3 Roche Tissue Diagnostics (Ventana)
    • 6.3.4 Visiopharm A/S
    • 6.3.5 Paige AI Inc.
    • 6.3.6 PathAI Inc.
    • 6.3.7 Hamamatsu Photonics KK
    • 6.3.8 Aiforia Technologies Oyj
    • 6.3.9 Indica Labs
    • 6.3.10 Sectra AB
    • 6.3.11 Pramana Inc.
    • 6.3.12 3DHISTECH Ltd.
    • 6.3.13 OptraSCAN Inc.
    • 6.3.14 Proscia Inc.
    • 6.3.15 Corista LLC
    • 6.3.16 Huron Digital Pathology
    • 6.3.17 XIFIN Inc.
    • 6.3.18 Akoya Biosciences
    • 6.3.19 Glencoe Software Inc.
    • 6.3.20 Deep Bio Inc.
    • 6.3.21 PathPresenter AI

7. Market Opportunities & Future Outlook

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Digital Pathology Image Analysis Market Report Scope

As per the scope of the report, digital pathology image analysis refers to the process of utilizing computer-based algorithms and software tools to analyze and interpret digital images of tissue samples obtained from pathology slides.

The digital pathology image analysis is segmented by software, and the software market is segmented into imaging management system software, image analysis software, and others. In terms of application, the market is segmented into disease diagnosis, drug discovery, and others. By end user the market is segmented into pharmaceutical & biotechnology companies, hospital and reference laboratories, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD) for the above segments.

By Software Imaging Management System Software
Image Analysis Algorithms
AI-powered Decision-Support Suites
Integration / Middleware Tools
Open-Source & Community Platforms
Others
By Application Disease Diagnosis
Drug Discovery
Companion Diagnostics
Education & Training
Teleconsultation & Remote Second Opinion
Quality Control & Regulatory Compliance
By End User Hospitals & Reference Laboratories
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations (CROs)
Others
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East GCC
South Africa
Rest of Middle East
South America Brazil
Argentina
Rest of South America
By Software
Imaging Management System Software
Image Analysis Algorithms
AI-powered Decision-Support Suites
Integration / Middleware Tools
Open-Source & Community Platforms
Others
By Application
Disease Diagnosis
Drug Discovery
Companion Diagnostics
Education & Training
Teleconsultation & Remote Second Opinion
Quality Control & Regulatory Compliance
By End User
Hospitals & Reference Laboratories
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations (CROs)
Others
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East GCC
South Africa
Rest of Middle East
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

How big is the Digital Pathology Image Analysis Market?

The market stands at USD 419.69 million in 2025 and is projected to reach USD 650.20 million by 2030 at a 9.15% CAGR.

Which region leads in revenue, and which grows fastest?

North America leads with 48.52% of 2024 revenue, while Asia-Pacific is forecast to grow at 10.32% CAGR to 2030.

Who are the key players in Digital Pathology Image Analysis Market?

Danaher Corporation, Koninklijke Philips NV, PathAI, Inc., Visiopharm A/S and Paige AI, Inc. are the major companies operating in the Digital Pathology Image Analysis Market.

Which is the fastest growing region in Digital Pathology Image Analysis Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

What software segment shows the highest growth?

AI-powered decision-support suites post the fastest 10.13% CAGR, reflecting rising demand for intelligent automation.

Page last updated on: June 16, 2025